HFB-200301 is under clinical development by HiFiBiO Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how HFB-200301’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HFB-200301 is under development for the treatment of advanced solid tumors including gastric cancer (third line), renal cell carcinoma (third line), melanoma (second, third line), sarcoma (second line), testicular germ cell tumor (third Line), cervical cancer (third Line), malignant mesothelioma (third Line), non-small cell lung cancer (third Line), soft tissue sarcoma, malignant pleural mesothelioma, lung adenocarcinoma and head and neck cancer squamous cell carcinoma (third Line). It acts by targeting TNFR2. It is administered through intravenous route. The therapeutic candidates are developed based on CelliGO platform and Drug Intelligence Science (DIS) platform.
HiFiBiO Therapeutics overview
HiFiBiO Therapeutics, a biotechnology company that engaged in providing antibody drug discovery services. The company is headquartered in United States.
For a complete picture of HFB-200301’s drug-specific PTSR and LoA scores, buy the report here.